Chemotherapy of advanced soft‐tissue sarcomas

Seminars in Surgical Oncology

Volumn 4, Issue 1, 1988, Pages 53-58

  Antman, Karen H ^a   Elias, Anthony D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

dacarbazine; doxorubicin; ifosfamide

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; IFOSFAMIDE;

BONE MARROW SUPPRESSION; HUMAN; MAJOR CLINICAL STUDY; REVIEW; SOFT TISSUE SARCOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DOXORUBICIN; DRUG EVALUATION; HUMAN; IFOSFAMIDE; RANDOM ALLOCATION; SARCOMA; SARCOMA, KAPOSI; SOFT TISSUE NEOPLASMS;

EID: 0023851260     PISSN: 87560437     EISSN: 10982388     Source Type: Journal    
DOI: 10.1002/ssu.2980040111     Document Type: Article

References (76)

1. Cancer statistics
2. Uterine sarcomas. Natural history, treatment and prognosis
3. Uterine sarcomas, an analysis of 69 patients
4. The value of radiation therapy in uterine sarcoma
5. Sarcoma of the uterus
6. Thoracic soft‐tissue sarcoma in Vietnam veterans exposed to agent orange
7. Antibodies to human T‐cell leukemia virus‐associated cell membrane antigens (HTLV‐MA) in patients with acquired immune deficiency syndrome (AIDS)
8. An overview of studies in adriamycin (NSC‐123127) in the United States
9. Phase II evaluation of adriamycin in human neoplasia
10. A clinical trial adriamycin (NSC 123127) in advanced sarcomas
11. A comparison of adriamycin versus vincristine and adriamycin, and cyclophospha‐mide for advanced sarcoma
12. Randomized comparison of adriamycin regimens for treatment of metastatic soft tissue sarcomas
13. Combination chemotherapy for soft tissue sarcomas: A phase III study
14. Dose response evaluation of adriamycin in human neoplasia
15. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
16. High dose methotrex‐ate (HDMTX) with citrovorum factor rescue (CFR) in the treatment of radiation‐induced sarcomas
17. High dose methotrexate with leucovorin rescue, Rationale and spectrum of antitumor activity
18. High dose methotrexate with leucovorin rescue plus vincristine in advanced sarcoma: A southwest oncology group study
19. High‐dose methotrexate followed by citrovorum factor reversal in patients with advanced cancer
20. High‐dose methotrexate as secondary chemotherapy in metastatic soft‐tissue sarcomas
21. “Single”‐agent activity of high‐dose methotrexate therapy with citrovorum factor rescue
22. Phase II clinical trail with high‐dose methotrexate therapy and citrovorum factor rescue
23. Phase II study of methotrexate (NSC 740) in solid tumors
24. Evaluation of bleo‐mycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma
25. A clinical study of 5‐fluorour‐acil
26. Effect of vincristine (NSC‐67574) on malignant solid tumors in children
27. Low doses of vincristine (NSC‐67574) for malignant disease
28. Therapeutic trials with VP‐16 and VM26
29. Epipodophyllotoxin therapy of childhood neoplasia. A comparative phase II analysis of VM‐26 and VP 16‐213
30. EORTC. Phase II study of cisplatinum CYVADIC‐resistant soft tissue sarcoma
31. Cis‐dichlorodia‐mineplatinum (II) in metastatic soft tissue sarcomas
32. Cis‐dichlorodia‐mineplatinum (II) in advanced soft tissue and bony sarcomas
33. Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus
34. A prelusive clinical trial of cyclophos‐phamide
35. Preliminary evaluation of the effect of cyclophosphamide on the course of human neoplasms
36. Sarcomas of soft tissue
37. High‐dose ifosfamide and mesna as continuous infusion over five days—a phase I/H trial
38. Clinical studies with uromi‐texan—an antidote against urotoxicity of holoxan. Preliminary results
39. Contribution to the treatment of malignant tumors with ifosfamide
40. Treatment of recurrent sarcomas with ifosfamide (IF)
41. Chemoth‐erapeutischeBehandlungsmoglichkeiten Bei Forgeschrittenen Sar‐komen
42. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma
43. High‐dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma
44. Phase II trial of ifosfamide (IFOS) with Mesna in patients with pediatrie malignant solid tumors
45. The combination ifosfamide/VP 16–213 in therapy of small cell bronchogenic carcinoma and other malignant tumors
46. Therapie pro‐gredienter Sarkome mit Etososid und Ifosfamide
47. Ifosfamide and vincristine in pediatrie tumors. A phase II study
48. Cyclophosphamide versus Ifosfamide: A randomized phase II trial in adult soft tissue sarcoma. Preliminary report of EORTC soft tissue and bone sarcomas group
49. Adriamycin (NSC‐123127) used alone and in combination for soft tissue and bony sarcomas
50. CYVADIC vs CYVADACT‐a randomized trial of cyclophosphamide (CY), vincristine (V), and adriamycin (A) plus either dacarbazine (DIC) or actinomycin‐D (DACT) in metastatic sarcomas
51. A randomized study of adriamycin with and without dimethyl trazenoimidazole carboxamide in advanced uterine sarcomas
52. Leiomyosarcoma: The Eastern Cooperative Oncology Group experience with 222 patients
53. Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin. and DTIC (CAD)
54. Survival and relapse patterns of complete responders in adults with advanced soft tissue sarcomas (ASTS), Proc
55. Protected Environment—Prophylactic Antibiotic program for malignant sarcoma: Randomized trial during remission induction chemotherapy
56. CYVADIC in advanced soft tissue sarcoma: A randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group
57. Effectiveness of combination of ifosfamide, vincristine and actinomycine D in inducing remission in rhabdomysarcoma in children. For the RMS groups of the International Society of Pediatrie Oncology (S1OP)
58. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: A phase I study
59. Adriamycin (A) and ifosfamide (I), a new effective combination in advanced soft tissue sarcoma; preliminary report of a phase II study of the EORTC soft tissue and bone sarcoma group
60. Chemotherapy of sarcomas with a combination of adriamycin and diemthyltrazeno‐imidazole‐carboxamide
61. Sarcoma chemotherapy
62. A comparative clinical trial evaluating the combination of actinomycin D, cyclophosphamide, and vincristine, and a single agent, methyl‐CCNU, in advanced sarcomas
63. Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas
64. Recent trends in treatment of soft tissue sarcomas‐Appendix A
65. Combination chemotherapy with adriamyin, cyclophosphamide and methotrexate in metastatic sarcomas
66. Methyl CCNU and adriamycin for patients with metastatic sarcomas
67. Combination chemotherapy with adriamycin and streptozotocin
68. Combined adriamycin, vincristine, and methotrexate
69. Combination chemotherapy of metastatic testicular germinal cell tumors and soft part sarcomas